ClinicalTrials.Veeva

Menu
T

The Retina Group of Washington | Chevy Chase, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

APL-2
bevacizumab
Zimura
JNJ-81201887
ranibizumab
Pegcetacoplan
zeaxanthin
Avacincaptad pegol
DHA
EPA

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

Trial sponsors

A
Astellas logo
C
I
Janssen (J&J Innovative Medicine) logo
National Institutes of Health (NIH) logo
N
The EMMES Corporation logo
University of Pennsylvania logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems